BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/26/2024 10:33:29 AM | Browse: 492 | Download: 1040
Publication Name World Journal of Hepatology
Manuscript ID 93516
Country Mali
ISSN 1948-5182 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4. 0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https: //creativecommons. org/Licenses/by-nc/4. 0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Editorial
Article Title Interleukin-mediated therapies in liver diseases and comorbidity effects
Manuscript Source Invited Manuscript
All Author List Nouhoum Bouare and Jean Delwaide
ORCID
Author(s) ORCID Number
Nouhoum Bouare http://orcid.org/0000-0002-8362-6740
Jean Delwaide http://orcid.org/0000-0001-7894-8123
Funding Agency and Grant Number
Corresponding Author Nouhoum Bouare, DSc, PhD, Research Scientist, Senior Lecturer, Senior Researcher, Department of Quality, Hygien, Biosafety/Biosecurity and Pharmacovigilence, National Institute of Public Health, Hippodrome Rue Hamilcar Cabral Bamako, Bamako 1771, Mali. nouhoumsamakoro@yahoo.fr
Key Words Cytokines; Interleukins; Liver diseases; Therapy; Comorbidity
Core Tip IL-mediated monotherapy and synergistic treatment experiments are certainly interesting for scientific insights. Overcoming clinical trials challenges a fortiori linked to the liver-comorbid condition, new drugs development models are being experienced, such as dissecting the molecular subphenotypes which favour disease progression, promoting the precision medicine through multiomics analysis, and promoting the safe, long-lasting and effective antiviral formulations. However, a judicious exploitation of newly available data, and applying related-useful findings pertaining to comorbidity pathway and a multidisciplinary approach, should efficiently address liver diseases management in a short-term a fortiori to avoid long-term complications.
Publish Date 2024-07-26 10:33
Citation

Bouare N, Delwaide J. Interleukin-mediated therapies in liver diseases and comorbidity effects . World J Hepatol 2024; 16(7): 980-989

URL https://www.wjgnet.com/1948-5182/full/v16/i7/980.htm
DOI https://dx.doi.org/10.4254/wjh.v16.i7.980
Full Article (PDF) WJH-16-980-with-cover.pdf